Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: flt3 targeting tri specific T cell engaging therapeutics - Harpoon Therapeutics

Next Previous
Search
Drug Profile

Research programme: flt3 targeting tri specific T cell engaging therapeutics - Harpoon Therapeutics

Alternative Names: FLT3 TriTACs®; FLT3-targeting T cell engager; FLT3-targeting TriTACs

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
  • 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck and Co
  • 10 Apr 2021 Flt3 targeting tri specific T cell engaging therapeutics - Harpoon Therapeutics is available for licensing as of 10 Apr 2021. https://www.harpoontx.com/contact/

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top